Summit is a leader in the field of utrophin modulation. Our most advanced utrophin modulator, ezutromid (SMT C1100), is in a Phase 2 clinical trial called PhaseOut DMD. PhaseOut DMD aims to provide proof of concept for ezutromid and utrophin modulation by measuring muscle fat infiltration, as well as by measuring utrophin protein and muscle fibre regeneration in muscle biopsies. Further information on this trial is available at: . We also have an online resource for the Duchenne community, which includes answers to frequently asked questions on our utrophin programme and clinical trials: .